Abstract: A latex composition including a dispersion of an amphiphilic copolymer in an aqueous medium, wherein the copolymer is: (i) a graft copolymer including a hydrophobic straight or branched chain carbon-carbon backbone having at least one hydrophilic side chain, wherein each chain is independently of formula (I), wherein R1 and R2 are each independently H1-C(O)WR4 or —C(O)Q; provided that at least one of R1 and R2 is the group —C(O)Q; or R1 and R2 together form a cyclic structure together with the carbon atoms to which they are attached.

Abstract: A functionalized homopolymer or copolymer of vinyl alcohol of the formula P—(R)n, where: P represents a straight or branched chain polymer backbone that is a homopolymer of vinyl alcohol or a copolymer of vinyl alcohol and at least one other monomer, the homopolymer or copolymer comprising one or more reactive coupling group; R represents an aminosilane-containing and/or an aminosilanol-containing side chain attached to the polymer backbone via the one or more reactive coupling group; and n represents the number of side chains, which are present in an amount from about 1 to about 25 mol % of the polymer backbone; and ink or coating compositions containing the functionalized polymer.

Abstract: There is described a vector able to express a transgene under the control of a promoter, the duration of expression being enhanced by the exposure of the vector to cytomegalovirus pp71 or a homologue thereof. Usually the vector will be a viral vector and Herpesvirus vectors are preferred. Suitable cytomegalovirus pp71 proteins include, but are not limited to, mouse, rat, chimpanzee, simian, equine and guinea pig pp71 proteins, but human pp71 is preferred. The vector may itself include the gene for expression of cytomegalovirus pp71.

Abstract: The present invention relates to a recombinant herpes simplex virus (HSV) viral vector genome which has substantially lost its transducing properties as a result of a DNA sequence change in the gene coding for Vmw65 protein and also comprises an expressable heterologous gene inserted into a region of the HSV genome which is non-essential for the culture of the virus, the gene being under the control of the immediate early (IE1) gene enhancer of cytomegalovirus (CMV) and to the use of the recombinant HSV genome in therapy and vaccination.

Abstract: A recombinant herpes simplex virus (HSV) viral vector genome which has substantially lost its transducing properties as a result of a DNA sequence change in the gene coding for Vmw65 protein and also contains an expressable heterologous gene inserted into a region of the HSV genome which is non-essential for the culture of the virus, the gene being under the control of the immediate early (IE1) gene enhancer of cytomegalovirus (CMV) and to the use of the recombinant HSV genome in therapy and vaccination.

Abstract: A herpes simplex virus type I (HSV-1) mutant capable of establishing latent infection in the absence of in vivo viral replication in neuronal cells and of expressing an inserted therapeutic gene, which comprising: (i) a DNA sequence change in the gene coding for Vmw65 protein, such as to substantially remove the transducing properties while retaining its structural role and thereby preventing in vivo replication, the DNA sequence change being achieved by a transition or transversion alteration of 1 to 72 base pairs, an oligonucleotide insert of 3 to 72 base pairs, or a deletion of 3 to 72 base pairs, at a position between amino acids 289 and 412 of the protein; and (ii) a therapeutic gene inserted into a region of the HSV-1 genome which is non-essential for culture of the virus, and a promoter therefor able to express the therapeutic gene in neuronal cells in vivo. The preferred insertion site for the therapeutic gene (e.g. tyrosine hydroxylase gene) is within the thymidine kinase gene of HSV in 1814.